Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy
Source abstract
Abstract
In the present study, a dual pH-responsive multifunctional nanoparticle system was designed for combining immunotherapy and chemotherapy to treat breast cancer through targeting immune cells and cancer cells. A proven anti-tumor immune regulator, R848, was encapsulated with poly(L-histidine) (PHIS) to form PHIS/R848 nanocores. Doxorubicin (DOX) was conjugated to hyaluronic acid (HA) through an acid-cleavable hydrazone bond linkage to synthesize polymeric prodrug HA-DOX, which was subsequently coated outside PHIS/R848 nanocores to form HA-DOX/PHIS/R848 nanoparticles. Ionization of PHIS around pH 6.5 (a pH value close to that of tumor microenvironment) switched the nature of this material from hydrophobic to hydrophilic, and thus triggered the release of R848 to exert immunoregulatory action. The rupture of hydrazone bond in HA-DOX at about pH 5.5 (pH of endo/lysosomes) accelerated the release of DOX to exert cytotoxic effects. In immune cells, PHIS/R848 nanocores exhibited strong immunoregulatory activities similar to those induced by free R848. In breast cancer cells overexpressing CD44, HA-DOX was specially internalized by CD44-mediated endocytosis and significantly inhibited the cell growth. In 4T1 tumor-bearing mice, HA-DOX/PHIS/R848 nanoparticles showed excellent tumor-targeting ability and remarkably inhibited the tumor growth by regulating tumor immunity and killing tumor cells. In summary, this multifunctional nanoparticle system could deliver R848 and DOX respectively to tumor microenvironment and breast cancer cells to achieve synergistic effects of immunotherapy and chemotherapy against breast cancer. Statement of significance Combination of immunotherapy and chemotherapy is becoming a promising new treatment for cancer. The major challenge is to target cancer and immune cells simultaneously and specifically. In this study, a dual pH-responsive multifunctional nanoparticle system based on poly(L-histidine) and hyaluronic acid was designed for co-loading R848 (immune-regulator) and doxorubicin (chemotherapeutic drug) through different encapsulation modes. By responding to the acidic pHs of tumor microenvironment and intracellular organelles, this multifunctional nanoparticle system could release R848 extracellularly and deliver DOX targetedly to breast cancer cells, thus achieving synergistic effects of immunotherapy and chemotherapy against breast cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Cancer statistics
2. Microenvironmental regulation of tumor progression and metastasis10.1038/nm.3394 ↗
3. “Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy10.1016/j.addr.2015.10.019 ↗
4. Prospects for combining targeted and conventional cancer therapy with immunotherapy10.1038/nrc.2017.17 ↗
5. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
6. Engineered nanoparticles for drug delivery in cancer therapy10.1002/anie.201403036 ↗
7. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
8. Stimuli-responsive polymers: biomedical applications and challenges for clinical translation10.1016/j.addr.2012.11.004 ↗
9. Hybrid nanoparticles for combination therapy of cancer10.1016/j.jconrel.2015.09.029 ↗
10. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer10.1056/NEJMoa1200694 ↗
11. Pembrolizumab for the treatment of non-small-cell lung cancer10.1056/NEJMoa1501824 ↗
12. Control of adaptive immunity by the innate immune system10.1038/ni.3123 ↗
13. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity10.1016/j.immuni.2011.05.006 ↗
14. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy10.4161/onci.20931 ↗
15. TLR7 and TLR8 as targets in cancer therapy10.1038/sj.onc.1210913 ↗
16. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-84810.1038/ni0602-499 ↗
17. Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy10.1016/j.jconrel.2017.04.011 ↗
18. Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy10.1016/j.biomaterials.2014.05.076 ↗
19. Super pH-sensitive multifunctional polymeric micelle10.1021/nl0479987 ↗
20. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis10.1038/nrc1713 ↗
21. Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)10.1016/j.jconrel.2007.08.006 ↗
22. Hyaluronan: a simple polysaccharide with diverse biological functions10.1016/j.actbio.2013.12.019 ↗
23. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery10.1016/j.jconrel.2015.02.008 ↗
24. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine10.3109/1061186X.2015.1052072 ↗
25. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer10.1016/j.biomaterials.2014.02.006 ↗
26. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems10.1039/C5CS00798D ↗
27. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer10.1016/j.jconrel.2010.04.006 ↗
28. PEGylated doxorubicin nanoparticles mediated by HN-1 peptide for targeted treatment of oral squamous cell carcinoma10.1016/j.ijpharm.2017.04.027 ↗
29. Conjugating an anticancer drug onto thiolated hyaluronic acid by acid liable hydrazone linkage for its gelation and dual stimuli-response release10.1016/j.carbpol.2015.04.024 ↗
30. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization10.1016/S0168-3659(03)00205-0 ↗
31. pH-sensitive nano-systems for drug delivery in cancer therapy10.1016/j.biotechadv.2013.11.009 ↗
32. pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery
33. Dendritic cells: specialized and regulated antigen processing machines10.1016/S0092-8674(01)00449-4 ↗
34. A Novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma10.1532/IJH97.04116 ↗
35. IRF-5 and NF-kappaB p50 co-regulate IFN-beta and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells10.1002/eji.201242792 ↗
36. Activation of dendritic cells: translating innate into adaptive immunity10.1016/j.coi.2003.11.007 ↗
37. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy10.1016/j.drudis.2016.12.009 ↗
38. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models10.1016/j.biomaterials.2015.02.002 ↗
39. Enhanced cellular internalization and on-demand intracellular release of doxorubicin by stepwise pH-/reduction-responsive nanoparticles10.1021/acsami.6b09604 ↗
40. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy10.1158/1078-0432.CCR-11-3028 ↗
41. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma10.1182/blood-2012-05-432393 ↗
42. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 810.1158/1535-7163.MCT-09-1198 ↗
43. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice10.1007/s00262-016-1823-8 ↗
44. TLR7 and TLR8 as targets in cancer therapy10.1038/sj.onc.1210913 ↗
45. Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model10.3892/mmr.2015.3885 ↗
46. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations10.1038/ni.3682 ↗